BioSpace News Archive

J&J Vision today announced the U.S. launch of expanded parameters for 1-DAY ACUVUE MOIST Brand Contact Lenses for ASTIGMATISM, a daily disposable contact lens that offers patients BLINK-STABILIZED Design for clear, stable vision and LACREON Technology that provides a cushion of moisture for long-lasting comfort.

The JV represents a global first in a collaboration to produce comprehensive precision pharmaceutical grade medicine, derived from medical botanicals.

The starter pack has been developed following CluePoints’ extensive market and industry research to better understand the challenges faced by clinical development organizations and CROs since the introduction of the ICH E6 (R2) addendum.

The award is to support a Phase 3 clinical trial to evaluate the safety and efficacy of MDR-101.

The poster presentation reported the final data on the Phase IIa study of RX-3117 monotherapy in metastatic pancreatic cancer.

In addition, Athenex intends to grant the underwriters a 30-day option to purchase up to an additional 645,000 shares of common stock at the public offering price.

A previously completed Phase II clinical trial of Oraxol in the second-line treatment of gastric cancer patients showed an encouraging overall median survival of 10.7 months.

Amoy Diagnostics announced that CFDA approved its Super-ARMS EGFR Mutation Test for use with plasma samples, as a companion diagnostic for NSCLC therapy with EGFR-TKIs on January 19.

With intuitive operation and a new advanced peak detection algorithm, this software supports review-by-exception to improve the speed and efficiency of multi-analyte data analysis.

Invetech has announced the appointment of David Kneen as VP, Cell Therapy.